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We studied the eﬀects of cannabinoids and acute immobilization stress on the regulation of GABA release in the olfactory
bulb. Glutamate-stimulated 3H-GABA release was measured in superfused slices. We report that cannabinoids as WIN55, 212-
2, methanandamide, and 2-arachidonoylglycerol were able to inhibit glutamate- and KCl-stimulated 3H-GABA release. This
eﬀect was blocked by the CB1 antagonist AM281. On the other hand, acute stress was able per se to increase endocannabinoid
activity. This eﬀect was evident since the inhibition of stimulated GABA release by acute stress was reversed with AM281 and
tetrahydrolipstatin.InhibitionoftheendocannabinoidtransportoritscatabolismshowedreductionofGABArelease,antagonized
by AM281 in control and stressed animals. These results point to endocannabinoids as inhibitory modulators of GABA release in
the olfactory bulb acting through an autocrine mechanism. Apparently, stress increases the endocannabinoid system, modulating
GABAergic synaptic function in a primary sensory organ.
1.Introduction
Cannabinoids comprise a family of lipids/eicosanoids,
derived from marijuana/Hashish (Cannabis sativa). They
may also be endogenous to animals (endocannabinoids) or
synthetically produced (cannabimimetic) [1, 2]. Cannabi-
noids play a critical neuromodulatory role in the central
and peripheral nervous system, as well as in the immune
system, being an emerging therapeutic target for several
disorders as addiction, obesity, nauseas and vomiting, pain,
mental disorders, spasticity, glaucoma, and others [1, 3–5].
Apparently, they may also be associated with an old and
widely used drug as acetaminophen/paracetamol, which is
metabolized to a bioactive cannabimimetic drug AM404, an
inhibitor of endocanabinoid uptake [6, 7].
Endocannabinoids (eCB) participate in intracellular sig-
naling, being synthesized upon stimulation and increase of
citoplasmatic Ca2+, exerting their eﬀect through at least
two G protein coupled receptors, CB1 and CB2, and the
vanilloid receptor (TRPV1) [5, 8–15]. It has been shown that
diﬀerent cannabinoids are able to inhibit, through activation
of CB1 receptors, the release of neurotransmitters, as GABA,
glutamate (Glu), acetylcholine, noradrenalin, and dopamine
from several SNS structures as cerebellum, hippocampus,
striatum, substancia nigra, cortex, and so forth [2, 16]. The
fatty acid amide hydrolase (FAAH) and monoacylglycerol
lipase (MGL) are important enzymes in the catabolism
of endocannabinoids and have been located in several
structures of the CNS and speciﬁcally FAAH in the olfactory
bulb [5, 17, 18]. Also the transporter of eCB is important in
regulating the activity of the cannabinoid system in the CNS
[5, 19, 20].
On the other hand, stress is the primary cause for fear
or anxiety state which is an adaptive response to a threat. It is
stillcontroversialwhethercannabinoidsregulatestress,emo-
tion, and mood disorders only through central mechanism
by regulating the hypothalamus-pituitary-adrenal (HPA)
axis and other CNS regions [5, 21] or also in combination
with more peripheral levels as sensory gating mechanisms of
odor, taste, touch, and so forth [22–25]. Several reports have2 International Journal of Cell Biology
shown that cannabinoids are able to modulate the release of
neurotransmitters (5HT, GABA, Glutamate, Opioids, etc.) at
the level of CNS nuclei as cerebral cortex, hippocampus, N.
Accumbens [2, 5, 16] which are associated to stress and anx-
iety response [13, 26, 27]. At the level of the hypothalamus-
pituitary–adrenal axis, the primary level to stress response,
an important association between endocannabinoid activity
and reduction of the stress response of this axis has been
observed [21]. At the periphery, CB1 receptors have been
shown to be present at several levels and are able to modulate
nociception [28–30].
Endogenous and exogenous cannabinoids are able to
modulate sensory perception, mood, anxious states, stress,
pain, and so forth [4, 5, 26, 31]. Depending of the dose
and time frame of cannabinoids exposure, they may exert
an anxiolytic or anxiogenic eﬀect, but generally anxiolytic at
low concentrations [4, 5, 26, 27]. However, no reports are
presently available of the eﬀect of stress and cannabinoids
on the synaptic regulation in olfactory bulb and speciﬁcally
the regulation of GABA release. GABA is an important
neurotransmitter in this structure [32–34] being able to act
as a sensory modulator.
In the olfactory bulb, high density of CB1 and vanilloid
receptor labeling have been described [8–10, 35] together
with the presence of the enzyme, fatty acid amide hydrolase
(FAAH) is one of the enzymes which catalyses the hydrolysis
of endocannabinoids [17, 18], and one of its precursors N-
arachidonoyl phosphatidylethanolamine [36].
On the other hand it is known that GABAergic granule
cells establish dendro-dendritic synapses with glutamatergic
mitral cells at the level of the external plexiform layer (EPL)
[37] and that 3H-GABA is released from granule cells using
high K+ and glutamate stimulation in a Ca2+-dependent
mode [38]. NMDA and non-NMDA receptors have been
described in the olfactory bulb [33, 37] which mediated
the Glu-stimulate release of 3H-GABA from granule cell
dendrites from EPL of rat olfactory bulb [39].
In the present work, we were interested to test whether
immobilization stress and cannabinoids were able to reg-
ulate GABA neurotransmission in the olfactory bulb. Here
we show for the ﬁrst time that synthetic cannabinoids
as methanandamide/met-arachidonylethanolamide (AEA),
WIN55,212-2 (Win), and 2-arachidonylglicerol (2AG) are
able to inhibit Glu- and K+-stimulated release of 3H-GABA
in this preparation. It is important to point out that the
use of the AEA in our experimental conditions was favored
because of its potency and resistance to encocannabinoid
metabolism [40, 41]. Inhibition of anandamide transport
with AM404 [42, 43] and its catabolism through FAAH with
URB597 [44–46] has a strong inhibitory eﬀect on stimulated
GABA release. Also an inhibitor of the synthesis of 2AG,
tetrahydrolipstatin (THL) [47] increases signiﬁcantly Glu-
stimulated GABA release; these results point to an important
endogenous eﬀect of endocannabinoids on the GABAergic
terminals in the olfactory bulb. Acute immobilization stress
is able to induce the release of endocannabinoids inhibiting
the Glu-stimulated GABA release, apparently through CB1
receptors.
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Figure 1: Microdissection of olfactory bulb slices. Rat Olfactory
bulb slices were separated by free-hand microdissection using
a dissection microscope equipped with a cold stage and used
immediatelyforthereleaseexperiments.(a)Complete400μmthick
olfactory bulb slice, as seen under the dissection microscope. (b)
Micro dissected layers of the bulb. A: Olfactory nerve layer. B:
Glomerular layer. C: External plexiform layer (EPL). D: Mitral cell
layer. E: Granule cell layer. F: Ependyma layer.
2. Methods
2.1. Acute Stress. Male Sprague-Dawley rats from IVIC,
weighing 250–300g, were housed 4 per cage of the following
size: 61 × 42 × 19cm. The animal room had controlled
temperature and a 12hr light dark cycle (06:00–18:00).
Animals were supplied with lab. Chow and water ad libitum.
Control animals were kept in the animal quarters. The
stressing procedures consisted in keeping the animals in a
restrainingcageforonehourinthemorning.Therestraining
cage was a rectangular Plexiglas box (6 × 5 × 12cm) with
the tail-gate adjusted to keep the rat well contained without
being able to turn from front to back.
All animal experiments were carried out in accordance
with the NIH guide for the care and use of Laboratory
animals. All eﬀorts were made to minimize animal suﬀering
and use the minimum necessary number of animals.
2.1.1. Slice Preparation and Microdissection. Male Sprague-
Dawley rats, weighing 250–300g, were quickly decapitated
using a guillotine, and 0.4mm slices of the olfactory bulb
were obtained using a McIlwain tissue chopper. Slices were
transferred to a Petri dish containing Krebs bicarbonate
solution under continuous oxygenation with 95% 02/5%
CO2. The EPL, which contains high density of granule
cell GABAergic dendrites [30], was separated by free-handInternational Journal of Cell Biology 3
microdissection using a dissection microscope equipped
with a cold stage and used immediately for the release exper-
iments (Figure 1). All these steps were carried out at 4◦C.
2.1.2. Release Studies. The method to study release was as
described by Jaﬀ´ e and Vaello [34]. Micro dissected EPL
(Figure 1(b)) was preincubated in 1.5mL Krebs bicarbonate
solution at 25◦Cf o r1 0 m i n .( i nm M :K C l2 , 5 ;K H 2P04
1.25; MgCl 1, NaCl 125; CaCl2 2; glucose 10, NaHC03 26;
aminooxyacetic acid (AOAA) 10μM; and equilibrated with
02/C02 to pH 7.4). 3H-GABA was added to a ﬁnal concentra-
tion of 0.1μM and incubation continued for 15min under
continuous oxygenation with 95% 02/5% CO2. The tissue
was then transferred to a 500uL superfusion chambers, and
superfused, at a rate of 500μL/min, with Krebs-bicarbonate
solution under continuous oxygenation. During the ﬁrst
35min, the tissue sections were washed with the Krebs solu-
tion,andthereafterthesuperfusatesampleswerecollected,at
2-minute intervals, using a fraction collector. Baseline level
of 3H-GABA release was collected for 14min, and 100μM
glutamate or 15mMKCl were added to the superfusate, for
4min. to stimulate 3H-GABA release. Aliquot of 400μL
was transferred to scintillation vials, and 2.6mL of a
scintillate solution, Aquasol (New England Nuclear), was
added. Radioactivity was measured by liquid scintillation
spectrometry. At the end of each experiment, the tissue was
dissolved in triton X-100, and the radioactivity counted.
The release of 3H-GABA was expressed as a percentage
of the total amount of radioactivity remaining in the tissue,
at the time of collection, released per minute. The evoked
release is expressed as the ratio of the evoked release, during
the highest 3min. release during stimulation, divided by the
basal release. Basal release was the mean value of the evoked
release during 2 fractions before and after the complete
release eﬀect of stimulation, multiplied by 3. These values
were treated with nonparametric statistical analysis using
Mann-Whitney two-tailed rank sum test [48].
2.2. Measurement of Corticosterone. Levels of corticosterone
in serum of control and stressed animals were measured
using the commercial Kit for rat corticosterone EIA (dsl:
diagnostic lab. Inc.USA).
2.3. Materials. KCl, KH2P04, MgCl, NaCl, CaCl2, glucose,
NaHC03 were from Merk, aminooxyacetic acid (AOAA) was
from Sigma-RBI. 4-Amino-n-[2,3-3H] butyric acid (3H-
GABA) was purchased from GE-Amersham. Aquasol was
from Perkin Elmers. All cannabinoid drugs and glutamate
were from Sigma-RBI and prepared as stock solutions in
DMSO as indicated by the provider.
3. Results
3.1. Levels of Corticosterone. Experimental animals were
immobilized as described in methods. Control and exper-
imental animals were sacriﬁced and blood taken for the
measurement of corticosterone. The serum of stressed and
control animals was stored at −20 until used with the
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Figure 2: Glutamate stimulated 3H-GABA release from olfactory
bulb: eﬀect of cannabinoids. Micro dissected EPL was incubated
with 0.1μM 3H-GABA and superfused with Krebs bicarbonate;
after a wash of 35min and 14min of basal release, 100μM
of Glu was added for 4min followed after 22min by 30mM
KCl stimulation (--). The cannabinoid agonist methanandamide
(AEA)(10μM) was added 14min before, during, and 12min after
Glu stimulation (--). The CB1 antagonist AM281 (10μM) was
added together with AEA in another set of experiments (--).
Results are expressed as % of the total 3H-GABA remaining in
the tissue at the time of collection, released per minute of one
representative experiment.
corticosterone Kit. The levels of corticosterone in stressed
rats were signiﬁcantly increased when compared to control
animals, being 161, 7 ± 17ng/mL in control (12) and 333,
9 ± 37ng/mL in stressed rats (12), with P<0.001 for the
Student t test statistical signiﬁcance.
3.2. Modulation of the Release of 3H-GABA by Cannabinoids.
Slices of the EPL layer of the olfactory bulb (Figure 1)
were incubated with 0,1μM of 3H-GABA, and after a
wash of 35min, the basal release level was measured
for 14min and stimulated with 100μM glutamate (Glu)
during 4min. As shown in Figure 2, a small but signiﬁcant
increase of 3H-GABA release was obtained. A second control
KCl stimulation (30mM), as a test for tissue viability,
was applied for 4min, giving a robust release response.
Perfusing the slices with 10μM of the cannabimimetic
drug, AEA for 14min before, during, and 12min after the
Glu stimulation reduced signiﬁcantly the 3H-GABA release
(Figures 2 and 3). The CB1 receptor antagonist AM281 [49,
50] when applied together with AEA was able to abolish
the eﬀect of AEA and even potentiate Glu-stimulated GABA
release (Figures 2 and 3); however, AM281 alone did not
show a signiﬁcant eﬀect on Glu-stimulated GABA release
at a concentration of 1uM. Even concentrations of the CB1
antagonist, as high as 10uM, were not able to show an eﬀect
on stimulated GABA release (results not shown). Also Win
(1uM) and 2AG (10uM), two cannabinoid agonist, showed
similar inhibition of the Glu-stimulated release.
Inhibition of GABA release was also observed when
the transport of endocannabinoids was inhibited with
20μM AM404 [42, 44]( Figure 4) or with 250μM URB597,4 International Journal of Cell Biology
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Figure 3: Eﬀect of cannabinoid agonist and antagonist on Glu-
stimulated 3H-GABA release. Micro dissected EPL was incubated
with 0.1μM 3H-GABA and superfused with Krebs bicarbonate;
after 49min of superfusion 100μM of Glu was added for 4min
(Glu). The cannabinoid agonist WIN55, 212-2, 1μM (Win),
2-arachidonoylglycerol 10μM (2AG,) methanandamide, 10μM
(AEA) were added 14 min before, during, and 12min after Glu
stimulation. The antagonist AM281 (1μM) was added alone or
together with AEA. Results are expressed as a ratio of the % of 3H-
GABA released as described in methods. ∗P<0.01 compared to its
Glu control, ns: not signiﬁcant using Mann Whitney test.
an inhibitor of the eCB degrading enzyme FAAH [44–46],
(Figure 4). The inhibitory eﬀects of AM404 and URB597
responseswerereversedbytheCB1antagonistAM281(1μM
or 10μM) (Figure 4).
Tetrahydrolipostatin (THL) 0,5μM, an inhibitor of the
synthesis of 2AG, [47] showed a strong potentiating eﬀect on
Glu-stimulated GABA release (Figure 4).
When GABA release was unspeciﬁcally stimulated with
15mMKCl, it was able to elicit a signiﬁcant release of 3H-
GABA which was inhibited by 2 cannabimimetic drugs as
Win (1 μM) or AEA (10μM) similar to the Glu-stimulated
eﬀect (Figure 5).
3.3. Modulation of the Release of 3H-GABA in Acute Stressed
Animals. Animals were immobilized for 1hr. as described
in methods. Immediately after the acute stress animals
were sacriﬁced, slices were used for the release experiments.
Control animals were not subjected to the stress procedure.
Asshown in Figures6 and 7, acutestress, by its own, wasable
to inhibit signiﬁcantly the Glu stimulated 3H-GABA release.
This eﬀect was reversed by 5μM AM281 the CB1R antagonist
(Figures 6 and 7).
When cannabinoid agonists AEA (10μM) and Win
(1μM) were added 14min before, during, and 12min after
the Glu-stimulation, a signiﬁcant inhibition of Glu stimu-
latedGABAreleasewasobservedbutwithnofurtherincrease
of the inhibitory eﬀect of stressed animals (Figure 7).
However, inhibiting the transport or the catabolism of endo-
cannabinoids with AM404 (20μM) or URB597, (250μM)
respectively, did signiﬁcantly enhance the inhibition of stress
on 3H-GABA release (Figure 8). Both inhibitory responses
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Figure 4: Eﬀect of drugs acting on cannabinoid metabolism
on Glu-stimulated 3H-GABA release. Micro dissected EPL was
incubated with 0.1μM3 H - G A B Aa n ds u p e r f u s e dw i t hK r e b s
bicarbonate; after 49min of superfusion, 100μMo fG l uw a sa d d e d
for 4min (Glu). Tetrahydrolipostatin 0.5uM (THL), an inhibitor
of synthesis of 2AG, AM404 20μM, the inhibitor of anandamide
transport, and URB597 250nM, an inhibitor of the anandamide
degrading enzyme FAAH, were added to the superfusing Krebs as
in the agonist experiments with or without the antagonist AM281
(1μM). Results are expressed as a ratio of the % of 3H-GABA
released as described in methods. ∗P<0.01 compared to Glu
control, &: signiﬁcant compared to its control using Mann Whitney
test.
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Figure 5: Release of KCl-stimulated 3H-GABA: eﬀect of cannabi-
noid agonist in control and acute stressed rats. Micro dissected EPL
was incubated with 0.1μM 3H-GABA and superfused with Krebs
bicarbonate; after of 49min of superfusion, 15mM of KCl was
added for 4min. The cannabinoid agonist Win 1μM or methanan-
damide 10μM (AEA) was added 14min before, during, and 12min
after KCl stimulation. Rats subjected to 1hr. immobilization stress
(Acute stress: AS) were sacriﬁced and olfactory bulb immediately
used for experiments. Results are expressed as a ratio of the % of
3H-GABA released as described in methods. ∗P<0.01 compared
to control using Mann Whitney test.International Journal of Cell Biology 5
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Figure 6: Glutamate-stimulated release of 3H-GABA: eﬀect of
cannabinoids in acute stressed rats. Rats subjected to 1hr. immobi-
lization stress (AS) were sacriﬁced and olfactory bulb immediately
used for experiments. Micro dissected EPL of control and stressed
animals were incubated with 0.1μM 3H-GABA and superfused
with Krebs bicarbonate; after a wash of 35min and 14min of basal
release, 100μM of Glu was added for 4min followed after 22min by
a 30mMKCl stimulation in control animals (-•-) and in acutely
stressed one (--). The cannabinoid antagonist AM281 (5μM)
was added 14min before, during, and 12min after Glu stimulation
in stressed animals (-- ) .R e s u l t sa r ee x p r e s s e da s%o ft h et o t a l
3H-GABA remaining in the tissue as described in methods of one
representative experiment.
1
1.2
1.4
1.6
1.8
2
Glu Win AS
AS
AEA AM281
R
a
t
i
o
3
H
-
G
A
B
A
r
e
l
e
a
s
e
∗
∗
∗
+G l u
&
Figure 7: Glutamate-stimulated release of 3H-GABA from rat
olfactory bulb: eﬀect of acute stress and cannabinoids. Rats sub-
jected to 1hr. immobilization stress were sacriﬁced, and olfactory
bulb immediately used for experiments. Micro dissected EPL of
controlandstressedanimalswereincubatedwith0.1μM3H-GAB A
andsuperfusedwithKrebsbicarbonate;after49minofsuperfusion,
100μM of Glu was added for 4min in control (Glu) and acutely
stressed (AS) animals. The cannabinoid agonist WIN55, 212-2,
1μM (Win), methanandamide, 10μM (AEA) was added 14min
before, during, and 12min after Glu stimulation. The antagonist
AM281 (5μM) was added during Glu stimulation. Results are
expressed as a ratio of the % of 3H-GABA released as described
in methods. ∗P<0.01 compared to Glu control, and P<0.01
compares to AS using Mann Whitney test.
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Figure 8: Eﬀect of drugs acting on cannabinoid metabolism on
Glu-stimulated 3H-GABA release of acutely stressed rats. Micro
dissectedEPLwasincubatedwith0.1μM3H-GABAandsuperfused
with Krebs bicarbonate; after 49min of superfusion, 100μMo fG l u
was added for 4min (Glu). Tetrahydrolipostatin 0,5uM (THL),
an inhibitor of synthesis of 2AG, AM404 20μM, the inhibitor
of anandamide transport, and URB597 250nM, an inhibitor of
the anandamide degrading enzyme FAAH, were added to the
superfusing Krebs as in the agonist experiments with or without the
antagonist AM281 (5μM). Results are expressed as a ratio of the %
of3H-GABAreleasedasdescribedinmethods. ∗P<0.01compared
to Glu control, &: signiﬁcant compared to its control using Mann
Whitney test.
were blocked when the CB1 antagonist AM281 (5μM) was
applied before and during the Glu stimulation (Figure 8).
AcutestressalsodiminishedtheKCl-(15mM)stimulated
release of 3H-GABA (Figure 5).
3.4. Modulation of Spontaneous Release of 3H-GABA. Spon-
taneous (basal) release of 3H-GABA was also modiﬁed in
some conditions. So when endocannabinoids are increased
with addition of AEA or when catabolism or transport is
inhibited with URB597 or AM404, respectively, basal 3H-
GABA release was signiﬁcantly diminished (Table 1). Also
the treatment with THL, the inhibitor of 2AG synthesis,
increased signiﬁcantly basal release of 3H-GABA release
(Table 1).
4. Discussion
For centuries it has been known that cannabinoids have a
wide range of eﬀects in the CNS, modulating perception
and mood. One of the earliest medical uses of cannabinoids
has been in pain treatment and many studies have brought
evidence for a central and peripheral action of cannabinoids
on pain. This is consistent with the presence of CB1 and
CB2 receptors at the level of CNS, spinal cord and peripheral
sensory nerves, with a complex mechanism of action and
interaction with other neuronal and immunological media-
tors[4,5].Atthelevelofothersensorysystems,assmell,little
is known, though high to moderate levels of CB1 and TRPV16 International Journal of Cell Biology
Table 1: Eﬀect of cannabinoids and acute stress on basal 3H-GABA
release. Micro dissected EPL was incubated with 0.1μM3 H - G A B A
and superfused with Krebs bicarbonate; after 47min of superfusion
a basal release was reached. Basal release is a % of release and was
measured as described in methods and is the median with 95%
conﬁdence interval of experiments. The abbreviations of the drugs
are as described above.
Control 0.50 (0.38–0.65)
n:65
AEA, 10uM 0.41∗ (0.31–0.53)
n:34
Win, 1uM 0.55ns (0.38–0.59)
n:22
AM281, 10uM 0.35∗ (0.3–0.47)
n:10
URB597, 250uM 0.34∗ (0.31–0.39)
n:15
AM 404, 20uM 0.37∗ (0.27–0.42)
n:16
THL, 0.5uM 0.94∗ (0.61–1.06)
n:6
2AG, 10 uM 0.53ns (0.41–0.6)
n:26
Acute Stress 0.42ns (0.36–0.54)
n:30
cannabinoid receptors have been described in the olfactory
bulb and olfactory epithelium [9–11, 35, 51]. The presence
of the catabolizing enzyme FAHH has also been described in
the olfactory bulb [17, 18]. Another evidence for the possible
importanceofcannabinoidintheOBandmoodistheuse,as
amodelofdepression,ofolfactorybulbectomy(OBX)which
can be reverted with cannabimimetics substances [52, 53].
In agreement with results obtained in other structures of
the CNS [2, 5, 16], we demonstrate that cannabinoids and
eCBs inhibit GABA release from granule cells of the olfactory
bulb. In fact, here we show that synthetic cannabinoids, AEA
and Win, or 2AG and eCB, are able to inhibit Glu- and
KCl-stimulated release of 3H-GABA in this structure. These
eﬀects are blocked by the CB1 antagonist AM281, arguing
in favor of the regulation of GABA release through CB1
receptors. Inhibition of the endocannabinoid transport with
AM404, or of the metabolic enzyme FAAH with URB597,
diminished Glu-stimulated GABA release, pointing to the
presence of an endocanabinoid regulation in the olfactory
bulb. Possibly, this inhibition is also mediated through CB1
receptors since the eﬀect of AM404 and URB597 is partially
reversed by the CB1 antagonist AM281. Other mechanisms
beside the action of CB1 receptors cannot be excluded since
eCBs may act at the level of other receptors or even as
intracellular messengers [5, 54].
2AG is apparently also an important endogenous can-
nabin in the OB since the inhibition of the synthesis of
2AG with THL caused a strong increase in stimulated GABA
release.
WealsoshowthatspontaneousGABAreleaseisinhibited
by treatments that increase cannabinoids levels and is in-
creased when the synthesis of 2AG is inhibited with THL.
Thus beside the stimulated, “on demand”, release, there is
also an important constitutive activity of eCB system, in
the olfactory bulb under our experimental conditions. Such
a dual mechanisms is however still controversial in other
experimental systems [5].
It is interesting to point out that the eﬀect of eCBs
that we have described occurs on the same GABA terminal
stimulated by Glu or KCl. This endocanabinoid action on
the EPL can be compared to a presynaptic autoreceptor
mechanism, described for many classical neurotransmitters
[55]( Figure 9). In the olfactory bulb, GABA release, stim-
ulated by the activation of inotropic (NMDA/AMPA) [37,
39], and metabotropic (mGlu1) [56] Glutamate receptors,
could induce synthesis of endocannabinoids from the same
GABA terminal (Figure 9). Upon synthesis and release,
eCBs would act directly on their receptors, on the same
terminal, inhibiting GABA release. This auto- modulation
of endocannabinoids on the same terminal where it is
synthesized and released would be comparable to a direct
negative feedback as in an autocrine system [55]( Figure 9),
which could inhibit GABA release together with the classical
retrograde synaptic regulation described for cannabinoids
[5, 57, 58].
At the level of the olfactory bulb, the precise localization
of the CB receptors is not known and the possibility of their
presence at the level of GABA as well as Glu terminals can
not be excluded. Further studies are needed to evaluate the
presence of an autocrine or/and a retrograde mechanism of
endocannabinoid action at the level of the olfactory bulb.
During acute stress, corticosterone levels were signiﬁ-
cantly increased when compared with the control animals,
indicating activation of the hypothalamus-pituitary-adrenal
(HPA) axis, since the activation of this system plays a pivotal
role in the stress response [59]. It is not clear whether
during stress, cannabinoids exert their eﬀect only through
central mechanisms or in combination with primary sensory
and peripheral systems as odor, taste, and so forth, with
a possible sensory gating mechanism [26, 60, 61]. The
change in perception during diﬀerent mood conditions and
pathologies is an interesting regulatory mechanism to cope
with stress situations.
The importance of eCB during stress or depression has
been documented at several levels of the CNS [1, 4, 5]. At
the level of the olfactory bulb, it has been shown that it may
function as a gating mechanism during stress [61, 62], and
indirect evidence of the importance of this sensory structure
in mood is shown with the olfactory bulbectomy model
of depression, which can be reverted with cannabimimetics
[52, 53]. In the present work, we show that in the olfactory
bulb, of acutely stressed rats, cannabinoids are probably able
to modulate primary sensory input through inhibition of
GABA release from granule cell dendrites (Figure 9). Thus,
at the level of the olfactory bulb, acute stress, by its own,
was able to inhibit GABA release, an eﬀect reversed by
the CB1 antagonist AM281, pointing to eCB activation inInternational Journal of Cell Biology 7
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Figure 9: Schematic diagram of a reciprocal synapse from the EPL of the olfactory bulb. Stimulation of mitral cells release glutamate,
depolarizing granule cells (1) through VGCC and/or NMDA/AMPA receptors (2) increasing cytoplasmic Ca2+. (3). This depolarization of
granule cells induces exocytosis of GABA. On the other hand, the increase of intracellular Ca2+ or/and the activation of mGlu receptors (2-
3) triggers the synthesis of endocannabinoids (anandamide/2AG) (4) which diﬀuse to the extracellular space (5) activating cannabinoid CB
receptors(6)atthelevelofthegranulecellsandpossiblealsothemitralcellsterminals.ThisactivationofCBreceptorsisabletoinhibitGABA
release(andeventuallyGlurelease?).TheeCBtransporter(7)andthecatabolicenzymeseliminateeCBs(8).Acutestressisapparentlyableto
inducesynthesisofeCB(4)andinhibitGABArelease;thiseﬀectcanbepotentiatedwhentheeCBstransporter(7)orthecatabolizingenzyme
(8) is blocked or when the synthesis of 2AG is inhibited with THL. NMDA/AMPA: inotropic glutamate receptors, mGluR: Metabotropic
glutamate receptor, VGCC:Voltage-gated Ca2+ channels, AEAT:Arachidonyl ethanol amine transporter,CBR:Cannabinoidreceptor, FAAH:
F a t t ya c i da m i d eh y d r o l a s e ,G A B A :γ-amino butyric acid, eCB: endocannabinoid, 2AG: 2-arachidonylglicerol, THL: tetrahydrolipostatin.
∗Modulator sites of acute immobilization stress.
the olfactory bulb under our experimental conditions. No
additional signiﬁcant changes in GABA release were caused
by cannabinoid agonists. However, when the catabolism or
the transport of endocannabinoids was blocked with the
CB1 antagonist, a potentiation of the stress eﬀect on GABA
release was observed suggesting a modulation at the level of
increased synthesis or decreased uptake and metabolism of
eCB during acute stress.
The endogenous inhibitory activity of cannabinoids
during acute stress, at the level of the olfactory bulb, can
also be seen with the inhibition of the synthesis of 2 AG
with THL, which strongly increased the stimulated release
of GABA. Apparently, during acute stress the increased eCB
levelsareabletoinhibitGABAreleasethroughCB1receptors
and in this way act as a gating mechanism and change odor
perception.
In control experiments, Glu-stimulated GABA release,
was not aﬀected by AM281, even at a high concentration,
10uM. However, in the presence of AEA, which inhibited
Glu-stimulated GABA release, AM281 at a lower concen-
tration of 1μM reverted the eﬀect of AEA, restoring and
even increasing GABA release above control levels. This
potentiation of GABA release could be explained in terms
of some unknown interaction between AEA and AM281
perhapsinvolvinganinverseagonistactionofAM281[5,63].
The endocannabinoid metabolism is apparently con-
stitutive in regulating GABA release since treatments that
increase eCB levels as URB597 and AM404 inhibited spon-
taneous GABA release. Again as in the experiments with
stimulated GABA release, AM281 showed an inverse eﬀect
on spontaneous release; at high concentrations as 10uM it
inhibited spontaneous GABA release, behaving as an agonist
and not an antagonist probably by acting at other modula-
tory sites [2, 5, 12, 13]. Nevertheless, a very clear eﬀect of
a spontaneous synthesis of the eCB 2AG was demonstrated
throughthepotentiationofthespontaneousreleaseofGABA
in the presence of THL, the inhibitor of the diacylglycerol
lipase, a pivotal enzyme in the synthesis of 2AG [47]. These8 International Journal of Cell Biology
ﬁndings would indicate that in the olfactory bulb a tonic
release of endocannabinoids could be observed in control
and stressed animals, similar to what has been described in
other preparations, as in CB1 receptor transfected cultured
hippocampal neurons [5, 64].
Apparently, in olfactory bulb, endocannabinoids release,
activated during acute stress, inhibits GABA release, thus
modulating the primary sensory input of odor to higher
levels of the CNS. In conclusion, endocannabinoids and
stress are able to modulate GABAergic synaptic function at
a sensory level (olfactory bulb). This modulation would be
through an autocrine regulation acting through CB1 recep-
tors.
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